Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
RenovoRx , Inc. (NASDAQ:RNXT) announced the results of its 2025 annual meeting of stockholders held Tuesday. According to a press release statement based on the company’s SEC filing, shareholders voted on three proposals.
First, all nominated directors were elected to serve one-year terms expiring at the 2026 annual meeting. The elected directors are Shaun R. Bagai, Ramtin Agah, M.D., Kirsten Angela Macfarlane, Laurence J. Marton, M.D., Una S. Ryan, O.B.E., Ph.D., D.Sc., and Robert J. Spiegel, M.D., FACP. Vote counts for the nominees ranged from approximately 9.5 million to 13 million shares in favor, with withheld votes ranging from about 76,000 to 3.6 million. There were 6.95 million broker non-votes for each nominee.
Second, shareholders approved two amendments to the company’s Amended and Restated 2021 Omnibus Equity Incentive Plan. The amendments include adding 913,794 shares of common stock, representing 2.5% of shares outstanding as of the record date, to the plan’s reserve and increasing the annual “evergreen” provision from 3% to 5% of outstanding shares. The vote tally was approximately 9.06 million shares in favor, 4.04 million against, 38,000 abstaining, and 6.95 million broker non-votes.
Third, shareholders ratified the appointment of Frank, Rimerman + Co. LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The ratification received about 19.13 million votes in favor, 949,000 against, and 5,700 abstentions.
A total of 36,551,752 shares of common stock were eligible to vote as of April 25, 2025, with approximately 20.1 million shares present or represented by proxy at the meeting, constituting a quorum.
This summary is based on information provided in a press release statement and the company’s SEC filing.
In other recent news, RenovoRx Inc. reported its financial results for the first quarter of 2025, exceeding internal revenue expectations with $200,000 in sales from its Renovocath device. The company is investing heavily in research and development, with expenses rising to $1.7 million, as it pursues growth through its Transarterial Microperfusion (TAMP) therapy platform and a Phase III clinical trial for its TIGRPAC project. RenovoRx’s strategic focus on innovation and market expansion positions it well for future growth, despite challenges such as high R&D costs and market competition. Additionally, Ascendiant Capital raised the stock price target for RenovoRx to $11.50 from $11.00, maintaining a Buy rating, reflecting confidence in the company’s potential growth. The firm’s analysis suggests significant potential returns, balancing high risks with large upside opportunities. RenovoRx is also exploring international market expansion and aims to become cash flow positive, with future revenue projections suggesting significant growth. The company is actively considering strategic partnerships to enhance its commercialization efforts, focusing on top cancer treatment centers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.